Good morning, and welcome to the Fulcrum Therapeutics conference call to discuss 12-week data from the 20-milligram cohort of the Phase 1b PIONEER trial of pociridir in sickle cell disease. [Operator ...
Flowserve Corporation posted Q4 2025 adjusted EPS of $1.11, including a $1.34 one-time asbestos-related item, on $1.2B revenue, missing by $60M. Learn more on FLS stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results